Lucid's EsoGuard wins Medicare payment at full list rate, but only claim by claim
The esophageal DNA test maker reports its best month yet for volumes, while the broader Medicare coverage policy remains under review with no stated end date.
Lucid Diagnostics has begun receiving Medicare payment for EsoGuard, its esophageal DNA test, at the full Clinical Laboratory Fee Schedule amount of $1,938.01 a test, the company said in its third-quarter 2026 update on 12 November.
The money is flowing through individual coverage decisions made by Novitas, the Medicare contractor, rather than through a settled national or regional policy. That route runs separately from the pending reconsideration of the MolDX Local Coverage Determination. Lucid's update gave no indication of when the reconsideration might be decided.
Commercial uptake is still modest in dollar terms. The company booked $1.2 million of revenue in the third quarter from 2,871 tests. It said it processed more than 1,800 tests in October alone, which it called a record month, a figure that would equate to a large share of the whole quarter's volume.
After the quarter ended, Lucid completed a $15.0 million Series C preferred stock financing. The material available did not disclose further terms.
Why it matters
- Medicare payment is being secured claim by claim, not under a settled coverage policy, so reimbursement may stay harder to predict until the MolDX reconsideration is resolved.
- A published fee schedule rate does not by itself guarantee payment; the contractor's individual coverage decisions still determine whether a test gets paid.
- Analysts and payers may watch whether October's record volume holds as claim-by-claim coverage stays in place for longer.
Company's press release (SEC filing): Lucid Diagnostics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Medicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
